NCT02659761 - Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

Human Immunodeficiency Virus

Interventions

DRUG

dolutegravir/abacavir/lamivudine

600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks

Trial Locations (1)

Mater Misericordiae University Hospital, Dublin